ANTIGEN-BINDING PROTEINS TARGETING SHARED NEOANTIGENS

1 . An antigen binding protein (ABP) that specifically binds to an HLA-PEPTIDE antigen comprising an HLA-restricted peptide complexed with an HLA Class I molecule, wherein the HLA-restricted peptide is located in the peptide binding groove of an α1/α2 heterodimer portion of the HLA Class I molecule, wherein the HLA Class I molecule and the HLA-restricted peptide are each selected from an HLA-PEPTIDE antigen as described in any one of SEQ ID NOs:10,755 to 29,364, and wherein the ABP comprises a T cell receptor (TCR) or antigen-binding fragment thereof.

2 - 3 . (canceled)

4 . The ABP of claim 1 , wherein the HLA-PEPTIDE antigen is selected from the group consisting of:

a. a RAS_G12D MHC Class I antigen comprising HLA-A*11:01 and the restricted peptide VVVGADGVGK;

b. a RAS_G12V MHC Class I antigen comprising HLA-A*11:01 and the restricted peptide VVVGAVGVGK;

c. a RAS_G12C MHC Class I antigen comprising HLA-A*02:01 and the restricted peptide KLVVVGACGV;

d. a CTNNB1_S45P MHC Class I antigen comprising HLA-A*03:01 and the restricted peptide TTAPPLSGK;

e. a RAS_G12D MHC Class I antigen comprising HLA-A*11:01 and the restricted peptide VVGADGVGK;

f. a RAS_G12V MHC Class I antigen comprising HLA-A*11:01 and the restricted peptide VVGAVGVGK;

g. a RAS_G12V MHC Class I antigen comprising HLA-C*01:02 and the restricted peptide AVGVGKSAL;

h. a RAS_G12V MHC Class I antigen comprising HLA-A*03:01 and the restricted peptide VVVGAVGVGK;

i. a TP53_K132N MHC Class I antigen comprising HLA-A*24:02 and the restricted peptide TYSPALNNMF;

j. a CTNNB1_S37Y MHC Class I antigen comprising HLA-A*02:01 and the restricted peptide YLDSGIHYGA;

k. a RAS_G12C MHC Class I antigen comprising HLA-A*03:01 and the restricted peptide VVVGACGVGK;

l. a RAS_G12C MHC Class I antigen comprising HLA-A*11:01 and the restricted peptide VVVGACGVGK;

m. a RAS_G12D MHC Class I antigen comprising HLA-A*03:01 and the restricted peptide VVVGADGVGK;

n. a RAS_Q61H MHC Class I antigen comprising HLA-A*01:01 and the restricted peptide ILDTAGHEEY; and

o. a TP53_R213L MHC Class I antigen comprising A*02:01 and the restricted peptide YLDDRNTFL.

5 - 7 . (canceled)

8 . The ABP of claim 1 , wherein the HLA-restricted peptide comprises a RAS G12 mutation, optionally wherein the G12 mutation is a G12C, a G12D, a G12V, or a G12A mutation.

9 - 50 . (canceled)

51 . An engineered cell expressing a receptor comprising the antigen binding protein of claim 1 .

52 . The engineered cell of claim 51 , wherein the engineered cell is a T cell, optionally wherein the T cell is selected from the group consisting of: a naive T (TN) cell, an effector T cell (TEFF), a memory T cell, a stem cell memory T cell (TSCM), a central memory T cell (TCM), an effector memory T cell (TEM), a terminally differentiated effector memory T cell, a tumor-infiltrating lymphocyte (TIL), an immature T cell, a mature T cell, a helper T cell, a cytotoxic T cell (CTL), a mucosa-associated invariant T (MALT) cell, a regulatory T cell (Treg), a TH1 cell, a TH2 cell, a TH3 cell, a TH17 cell, a TH9 cell, a TH22 cell, a follicular helper T cell, an natural killer T cell (NKT), an alpha-beta T cell, and a gamma-delta T cell.

53 - 55 . (canceled)

56 . The engineered cell of claim 51 , wherein the engineered cell is an autologous cell of a subject.

57 . The engineered cell of claim 56 , wherein the subject is known or suspected to have cancer.

58 - 61 . (canceled)

62 . The engineered cell of claim 56 , wherein the ABP comprises a T cell receptor (TCR) or an antigen-binding portion thereof, and wherein a polynucleotide encoding the T cell receptor (TCR) or antigen-binding portion thereof is inserted in an endogenous TCR locus.

63 . (canceled)

64 . An isolated polynucleotide or set of polynucleotides encoding the ABP of claim 1 or an antigen-binding portion thereof.

65 - 70 . (canceled)

71 . A pharmaceutical composition comprising the antigen binding protein of claim 1 and a pharmaceutically acceptable excipient.

72 . (canceled)

73 . A method of stimulating an immune response in a subject, comprising administering to the subject an antigen binding protein (ABP) that specifically binds to an HLA-PEPTIDE antigen comprising an HLA-restricted peptide complexed with an HLA Class I molecule, wherein the HLA-restricted peptide is located in the peptide binding groove of an α1/α2 heterodimer portion of the HLA Class I molecule, wherein the HLA Class I molecule and the HLA-restricted peptide are each selected from an HLA-PEPTIDE antigen as described in any one of SEQ ID NOs:10,755 to 29,364, and wherein the ABP comprises a T cell receptor (TCR) or antigen-binding fragment thereof, optionally wherein the subject has cancer, optionally wherein the cancer is selected from a solid tumor and a hematological tumor.

74 - 75 . (canceled)

76 . The method of claim 73 , wherein the cancer expresses or is predicted to express an HLA-PEPTIDE antigen or HLA Class I molecule as described in any one of SEQ ID NOs:10,755 to 29,364, and wherein the ABP binds to the HLA-PEPTIDE antigen, optionally wherein the cancer expresses or is predicted to express an HLA-PEPTIDE antigen comprising an HLA-restricted peptide complexed with an HLA Class I molecule, wherein the HLA-restricted peptide is located in the peptide binding groove of an α1/α2 heterodimer portion of the HLA Class I molecule, wherein the HLA Class I molecule and the HLA-restricted peptide are each selected from an HLA-PEPTIDE antigen as described in any one of SEQ ID NOs:10,755 to 29,364, and wherein the ABP binds to the HLA-PEPTIDE antigen.

77 - 154 . (canceled)

155 . The ABP of claim 1 , ABP comprises an alpha-CDR3 amino acid sequence and corresponding beta-CDR3 amino acid sequence selected from the group consisting of the sequences shown in Tables 1C. 2 and 1C. 3.

156 . The ABP of claim 155 , wherein the ABP further comprises an alpha variable (“V”) segment, an alpha joining (“J”) segment, a beta variable (“V”) segment, a beta joining (“J”) segment, optionally a beta diversity (“D”) segment, and optionally a beta constant region selected from the group consisting of the regions shown in Tables 1C. 2 and 1C. 3 corresponding to the alpha-CDR3 amino acid sequence and corresponding beta-CDR3 amino acid sequence.

157 . The ABP of claim 155 , wherein the ABP comprises an alpha variable region and corresponding beta variable region comprising the amino acid sequences selected from the sequences shown in Tables 1A. 2 and 1A. 3 corresponding to the alpha-CDR3 amino acid sequence and corresponding beta-CDR3 amino acid sequence.

158 . An antigen binding protein (ABP) that specifically binds to an HLA-PEPTIDE antigen comprising an HLA-restricted RAS peptide complexed with an HLA Class I molecule, wherein the HLA-restricted peptide is located in the peptide binding groove of an α1/α2 heterodimer portion of the HLA Class I molecule, wherein the HLA-restricted RAS peptide comprises at least one alteration that makes HLA-restricted RAS peptide sequence distinct from the corresponding peptide sequence of a wild-type RAS peptide, and wherein the ABP comprises an alpha-CDR3 amino acid sequence and corresponding beta-CDR3 amino acid sequence selected from the group consisting of the sequences shown in Tables 1C. 2 and 1C. 3.

159 . (canceled)

160 . The ABP of claim 158 , wherein the HLA-PEPTIDE antigen is (a) a RAS_G12C MHC Class I antigen comprising HLA-A*02:01 and the restricted peptide KLVVVGACGV, or (b) a RAS G12V MHC Class I antigen comprising HLA-A*11:01 and the restricted peptide VVGAVGVGK.

161 . The ABP of claim 160 , wherein the ABP comprises an alpha-CDR3 amino acid sequence and corresponding beta-CDR3 amino acid sequence selected from the group consisting of the sequences shown in Table 1C. 2 or Table 1C. 3.

162 . The ABP of claim 161 , wherein the ABP further comprises an alpha variable (“V”) segment, an alpha joining (“J”) segment, a beta variable (“V”) segment, a beta joining (“J”) segment, optionally a beta diversity (“D”) segment, and optionally a beta constant region selected from the group consisting of the regions shown in Table 1C. 2 or Table 1C. 3 corresponding to the alpha-CDR3 amino acid sequence and corresponding beta-CDR3 amino acid sequence.

163 . The ABP of claim 161 , wherein the ABP comprises an alpha variable region and corresponding beta variable region comprising the amino acid sequences selected from the sequences shown in Table 1A. 2 or Table 1A. 3 corresponding to the alpha-CDR3 amino acid sequence and corresponding beta-CDR3 amino acid sequence.

164 - 167 . (canceled)